CytomX Therapeutics Inc (CTMX) - Total Assets
Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) holds total assets worth $158.25 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CTMX total equity for net asset value and shareholders' equity analysis.
CytomX Therapeutics Inc - Total Assets Trend (2013–2024)
This chart illustrates how CytomX Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
CytomX Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
CytomX Therapeutics Inc's total assets of $158.25 Million consist of 89.0% current assets and 11.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 31.6% |
| Accounts Receivable | $3.10 Million | 2.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $583.00K | 0.5% |
| Goodwill | $949.00K | 0.8% |
Asset Composition Trend (2013–2024)
This chart illustrates how CytomX Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CytomX Therapeutics Inc (CTMX) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CytomX Therapeutics Inc's current assets represent 89.0% of total assets in 2024, an increase from 65.3% in 2013.
- Cash Position: Cash and equivalents constituted 31.6% of total assets in 2024, down from 61.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 18.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 2.6% of total assets.
CytomX Therapeutics Inc Competitors by Total Assets
Key competitors of CytomX Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
CytomX Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.64 | 1.04 | 4.76 |
| Quick Ratio | 3.64 | 1.04 | 4.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $108.19 Million | $4.95 Million | $255.90 Million |
CytomX Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between CytomX Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.99 |
| Latest Market Cap to Assets Ratio | 5.88 |
| Asset Growth Rate (YoY) | -40.3% |
| Total Assets | $120.53 Million |
| Market Capitalization | $708.24 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values CytomX Therapeutics Inc's assets at a significant premium (5.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: CytomX Therapeutics Inc's assets decreased by 40.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CytomX Therapeutics Inc (2013–2024)
The table below shows the annual total assets of CytomX Therapeutics Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $120.53 Million | -40.27% |
| 2023-12-31 | $201.79 Million | -22.65% |
| 2022-12-31 | $260.89 Million | -23.13% |
| 2021-12-31 | $339.41 Million | -5.37% |
| 2020-12-31 | $358.66 Million | +5.09% |
| 2019-12-31 | $341.28 Million | -25.34% |
| 2018-12-31 | $457.11 Million | +14.95% |
| 2017-12-31 | $397.64 Million | +99.69% |
| 2016-12-31 | $199.13 Million | +0.97% |
| 2015-12-31 | $197.22 Million | +169.93% |
| 2014-12-31 | $73.06 Million | +415.14% |
| 2013-12-31 | $14.18 Million | -- |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic w… Read more